Key Segmentation:
By Type
-
Live-Attenuated
-
Inactivated
-
Subunit
-
mRNA
-
Viral Vector
-
Conjugate
-
Others
By Administration Route
-
Intramuscular
-
Subcutaneous
-
Oral
-
Intradermal
By Disease Target
-
COVID-19
-
Influenza
-
Hepatitis
-
Measles
-
Polio
-
HPV
-
Others
By Age Group
-
Pediatrics
-
Adolescent
-
Adult
-
Geriatrics
By End User
-
Hospitals
-
Clinics
-
Research & Academic Institutes
-
Others
By Distribution Channel
-
Hospital Pharmacy
-
Retail Pharmacy
-
Online Pharmacy
-
Government Programs
-
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Ans: North America dominated the market with a 34.56% share in 2025, while Asia-Pacific is the fastest-growing region with a CAGR of 5.89% during 2026–2035.
Ans: Inactivated vaccines dominated with a 28.74% share in 2025, while mRNA vaccines are projected to record the fastest growth with a 7.12% CAGR during 2026–2035.
Ans: Growth is driven by rising infectious diseases, expanding immunization programs, increasing vaccine awareness and rapid advancements in mRNA and viral vector technologies.
Ans: The market is valued at USD 44.26 Billion in 2025 and is projected to reach USD 68.28 Billion by 2035.
Ans: The Human Vaccines Market is expected to grow at a CAGR of 4.43% during the forecast period 2026–2035.